Nanna MG, Doan QV, Fabricatore A, Faurby M, et al. Population-level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial. Diabetes Obes Metab 2025;27:3442-3452.
PMID: 40183412